The global Artificial Intelligence (AI) in Oncology market size is predicted to grow from US$ 1103 million in 2025 to US$ 3929 million in 2031; it is expected to grow at a CAGR of 23.6% from 2025 to 2031.
A variety of anticancer drugs are discovered, and their mechanism of action is predicted by using artificial intelligence. Various medicines and cancers are able to react differently; this information from screening processes reveals the links between therapeutic activities and the cancer genome.
AI is also used to fight against resistance to anticancer drugs. Cancer treatment, imaging, screening, and medication are various domains in which AI is used. Among these, cancer imaging is the most innovative. The advancement of technology and the use of AI in cancer diagnostics drive the expansion of the healthcare industry.
The artificial tools require low-cost diagnostic processes and quick detection data reporting.
Key Features
- Market overview and predictions for growth
- Comprehensive analysis by region and market sector
- Insights on product segmentation and key market trends
Segmentation by Type
- Hardware
- Software and Services
Segmentation by Application
- Hospitals
- Diagnostic Centers
- Pharmaceutical Companies
- Research Institutes
- Others
Market by Region
- Americas
- APAC
- Europe
- Middle East & Africa
Company's Coverage
- Azra AI
- Concert.AI
- Digital Diagnostics Inc.
- GE Healthcare
- Intel
- IBM
- Path AI
- NVIDIA
- Median Technologies
- Siemens Healthineers
Key Questions Addressed in this Report
- What are the key trends driving the market?
- How do market shares vary by region?
- What are the competitive strategies of leading companies?
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market